# Ipamorelin vs Sermorelin — What the Research Compares > Ipamorelin vs sermorelin: receptor targets, signaling pathways, studied indications, and published data compared. A research literature digest, not a clinical recommendation. ## The Fundamental Distinction The ipamorelin vs sermorelin comparison begins at the receptor level. Ipamorelin binds GHS-R1a — the ghrelin receptor on pituitary somatotrophs. Sermorelin binds GHRHR — the GHRH receptor. These are distinct receptor families with different endogenous ligands (ghrelin vs GHRH), different intracellular signaling cascades (Gq/11/calcium vs cAMP/PKA), and different physiologic roles [1][16]. The downstream effect is the same: GH release from pituitary somatotrophs. But the mechanism is entirely different, and the two pathways are complementary — which is the mechanistic basis for combining ipamorelin with sermorelin or CJC-1295 in research protocols. This page addresses the three-way comparison (ipamorelin, sermorelin, CJC-1295) and the secondary comparison with tesamorelin. It is a research-literature comparison, not a clinical recommendation. Neither ipamorelin nor sermorelin is FDA approved for GH-axis indications. ## Ipamorelin vs Sermorelin: Mechanistic Comparison Sermorelin is a synthetic 29-amino-acid fragment of GHRH. It binds GHRHR and stimulates pulsatile GH release through the cAMP/PKA pathway. Sermorelin has a very short half-life (~10–20 minutes in plasma), similar in concept to the pulsatile approach of ipamorelin but through an entirely different receptor [16]. Ipamorelin's half-life is also short — biexponential plasma decay in rat IV studies (Johansen et al. 1998), consistent with the multiple-injections-per-day approach in published protocols [9]. The two compounds therefore share a pulsatile dosing rationale while using different receptor targets. Key differences in the published literature: - **Selectivity**: Ipamorelin does not elevate ACTH, cortisol, or prolactin at GH-releasing doses; sermorelin's selectivity profile has not been characterized in the same direct comparative manner [1]. - **Human data**: Neither compound has published human controlled trials for GH-releasing or anabolic endpoints. Sermorelin's clinical trial history predates the modern trial-registration era; published human data is limited. - **Combination with the other pathway**: Combining sermorelin (GHRHR) or CJC-1295 (GHRHR) with ipamorelin (GHS-R1a) is theorized to produce supraadditive GH release based on complementary receptor pharmacology [16][18]. - **Regulatory status**: Neither is FDA approved. Sermorelin was previously available through compounding pharmacies but has faced the same 503A/503B compounding restrictions as ipamorelin in recent years. ## Ipamorelin vs Tesamorelin Ipamorelin vs tesamorelin involves a more fundamental mechanistic gap. Tesamorelin is an FDA-approved GHRH analog for a specific indication: HIV-associated lipodystrophy (visceral adiposity in patients on antiretroviral therapy). The FDA-approved dose is 2 mg subcutaneous daily [14]. A 2026 meta-analysis confirmed tesamorelin's efficacy in reducing visceral adipose tissue and hepatic fat in HIV-associated lipodystrophy — the indication it was approved for. Tesamorelin acts at GHRHR; ipamorelin acts at GHS-R1a. They are distinct receptor classes. The comparison is often framed as 'which produces more fat loss,' but this misframes the evidence. Tesamorelin's visceral fat reduction in HIV lipodystrophy is an FDA-reviewed finding in a specific population under a specific indication. Ipamorelin has not been studied for body composition endpoints in controlled human trials. ## Ipamorelin vs GHRP-6: Selectivity Profile GHRP-6 activates appetite-stimulating pathways and raises cortisol and prolactin significantly in the same dose range that produces GH release. Ipamorelin's selectivity at GHS-R1a spares these pathways in preclinical models, producing cleaner GH pulses without significant orexigenic effects at the published doses [1][2]. The 1998 Raun paper's direct comparison at equimolar doses is the foundational reference for this distinction. ## References [1] Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. https://pubmed.ncbi.nlm.nih.gov/9849822/ [2] Raun K, et al. Ipamorelin selectivity data: GHRP-2 and GHRP-6 comparison. Eur J Endocrinol. 1998;139(5):552–561. https://pubmed.ncbi.nlm.nih.gov/9849822/ [9] Johansen PB, et al. Pharmacokinetics of ipamorelin with emphasis on nasal absorption. Xenobiotica. 1998;28(11):1083–1091. https://pubmed.ncbi.nlm.nih.gov/9879640/ [12] Teichman SL, et al. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. https://pubmed.ncbi.nlm.nih.gov/16352683/ [14] NIH NLM. Tesamorelin — LiverTox. NIH Bookshelf. 2023. https://www.ncbi.nlm.nih.gov/books/NBK548730/ [16] Raun K, et al. Ipamorelin — GHS-R1a vs GHRHR receptor family distinction. Eur J Endocrinol. 1998;139(5):552–561. https://pubmed.ncbi.nlm.nih.gov/9849822/ [18] Frohman LA, Kineman RD. Pulsatile GH secretion persists during continuous CJC-1295 stimulation. J Clin Endocrinol Metab. 2006. https://pubmed.ncbi.nlm.nih.gov/17018654/ [19] Sackmann-Sala L, et al. Activation of GH/IGF-1 axis by CJC-1295 in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471–477. https://pubmed.ncbi.nlm.nih.gov/19386527/ --- A pastel-cloud reading of the ipamorelin literature — soft pulsatile pharmacology summarized from the peer-reviewed record, held by no clinic and sold by no one.